Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,119
  • Shares Outstanding, K 68,335
  • Annual Sales, $ 67,450 K
  • Annual Income, $ -27,130 K
  • 60-Month Beta 1.77
  • Price/Sales 1.69
  • Price/Cash Flow N/A
  • Price/Book 4.41
Trade CDXC with:

Options Overview Details

View History
  • Implied Volatility 181.89% ( +40.07%)
  • Historical Volatility 103.40%
  • IV Percentile 90%
  • IV Rank 11.35%
  • IV High 1,235.96% on 06/06/22
  • IV Low 46.93% on 12/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 6,625
  • Open Int (30-Day) 6,412

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.09
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +4.37%
on 06/16/22
2.3700 -29.54%
on 06/10/22
-0.1100 (-6.18%)
since 06/01/22
3-Month
1.5100 +10.60%
on 05/13/22
2.7600 -39.49%
on 04/04/22
-0.8800 (-34.51%)
since 04/01/22
52-Week
1.5100 +10.60%
on 05/13/22
10.5400 -84.16%
on 07/22/21
-8.1300 (-82.96%)
since 07/01/21

Most Recent Stories

More News
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several...

CDXC : 1.6700 (unch)
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border...

CDXC : 1.6700 (unch)
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22 nd Annual Consumer Growth and...

CDXC : 1.6700 (unch)
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen ® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on...

CDXC : 1.6700 (unch)
ChromaDex to Present at the LD Micro Invitational

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12 th annual Invitational. This...

CDXC : 1.6700 (unch)
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint...

CDXC : 1.6700 (unch)
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients , a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP TM ) with a 2022...

CDXC : 1.6700 (unch)
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 1.6700 (unch)
BIOVF : 21.9225 (-1.56%)
ChromaDex Corporation Reports First Quarter 2022 Financial Results

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.

CDXC : 1.6700 (unch)
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADCT : 8.54 (+7.42%)
CDXC : 1.6700 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

3rd Resistance Point 1.8900
2nd Resistance Point 1.8300
1st Resistance Point 1.7500
Last Price 1.6700
1st Support Level 1.6100
2nd Support Level 1.5500
3rd Support Level 1.4700

See More

52-Week High 10.5400
Fibonacci 61.8% 7.0905
Fibonacci 50% 6.0250
Fibonacci 38.2% 4.9595
Last Price 1.6700
52-Week Low 1.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar